Compositions of alpha-1 antitrypsin fusion molecules

• US 10,450,384 B2
• Filed: 03/14/2018
• Issued: 10/22/2019
• Est. Priority Date: 06/24/2011
• Status: Active Grant

• Current Assignee: Konkuk University, The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Dinarello, Charles A., Kim, Soohyun
• Primary Examiner(s): Mertz, Prema M
• Application Number:
  US15/921,469
• Publication Number:
  US 20180208681A1
• Time in Patent Office: 587 Days
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/8125 Alpha-1-antitrypsin
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins

Abstract

Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

Claims

1. An isolated fusion polypeptide comprising at least one human alpha-1 antitrypsin (AAT) polypeptide comprising an amino acid sequence selected from the group consisting of an AAT polypeptide sequence represented by SEQ ID NO:

52, SEQ ID NO;

53, or SEQ ID NO;

54 wherein the AAT polypeptide is operably linked to an immunoglobulin Fc polypeptide through a linker and wherein the Fc polypeptide comprises an Fc polypeptide of IgG1, IgG2, IgG3, IgG4 or IgD.

2. The isolated fusion polypeptide according to claim 1, wherein the Fc polypeptide comprises an Fc polypeptide of IgG4.

3. The isolated fusion polypeptide according to claim 1, wherein the AAT polypeptide is SEQ ID NO:

52, or SEQ ID NO;

54.

4. The isolated fusion polypeptide according to claim 1, wherein the fusion polypeptide is formed by linking the at least one human alpha-1 antitrypsin (AAT) polypeptide through its N terminus to the linker.

5. The isolated fusion polypeptide according to claim 1, further comprising a pharmaceutically acceptable excipient.

6. A kit comprising the isolated fusion polypeptide according to claim 1, further comprising a container.